Say Hello!
Don’t be shy.

   

Sygnature Discovery Tag

XenoGesis has been acquired by leading drug discovery CRO, Sygnature Discovery, strengthening the combined DMPK offering and enhancing existing capabilities and expertise. This latest acquisition by Sygnature serves to meet the increasing demand for DMPK services and boosts the company’s reach into the pre-clinical space. XenoGesis’ novel...

Great news, at BioCity based Sygnature Discovery we’re further strengthening our oncology and immuno-oncology capabilities with the acquisition of Alderley Oncology, a focused in vivo pharmacology service provider which undertakes high quality in vivo services for cancer drug discovery. The acquisition will add significant in-house expertise at Sygnature in...

Sygnature Discovery, the UK's largest independent provider of integrated drug discovery resource and expertise, has appointed Dr Bruce Sargent as Strategic Business Development Lead for North America to assist with the company’s ambitious growth plans for the USA and Canada. Sygnature Discovery is expanding its business...

X
X
X
X